Redmile Group LLC Has $11.90 Million Stock Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Redmile Group LLC increased its position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 944.4% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,164,126 shares of the company’s stock after purchasing an additional 1,956,923 shares during the period. Redmile Group LLC’s holdings in Ventyx Biosciences were worth $11,903,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in VTYX. Tower Research Capital LLC TRC grew its position in Ventyx Biosciences by 1,424.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 19,927 shares of the company’s stock worth $49,000 after purchasing an additional 18,620 shares in the last quarter. Federated Hermes Inc. bought a new stake in Ventyx Biosciences in the fourth quarter worth about $50,000. Norden Group LLC bought a new position in Ventyx Biosciences during the first quarter valued at $59,000. China Universal Asset Management Co. Ltd. increased its holdings in Ventyx Biosciences by 66.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,385 shares of the company’s stock worth $63,000 after acquiring an additional 4,553 shares during the last quarter. Finally, Aigen Investment Management LP bought a new stake in shares of Ventyx Biosciences in the fourth quarter valued at approximately $65,000. 97.88% of the stock is owned by institutional investors.

Analyst Ratings Changes

VTYX has been the topic of a number of recent research reports. HC Wainwright reissued a “neutral” rating and set a $6.00 price objective on shares of Ventyx Biosciences in a report on Thursday, June 13th. Oppenheimer lowered their price target on Ventyx Biosciences from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Thursday, June 6th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $15.75.

Ventyx Biosciences Trading Down 22.7 %

VTYX stock traded down $0.67 during midday trading on Monday, hitting $2.28. The company had a trading volume of 4,121,144 shares, compared to its average volume of 2,524,112. The stock has a market cap of $160.74 million, a price-to-earnings ratio of -0.70 and a beta of 0.40. Ventyx Biosciences, Inc. has a 52 week low of $1.87 and a 52 week high of $38.20. The stock’s 50 day moving average price is $3.17 and its 200 day moving average price is $4.17.

Ventyx Biosciences (NASDAQ:VTYX) last issued its earnings results on Thursday, May 9th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.05. During the same quarter in the previous year, the company earned ($0.68) earnings per share. Analysts predict that Ventyx Biosciences, Inc. will post -2.31 earnings per share for the current year.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.